The debate supports treating this as a validation program before ranking it as a therapy. Perturbation should move a proximal molecular phenotype, then a disease-relevant phenotype, in that order.
Curated pathway from expert analysis
flowchart TD
A["m6A RNA Modification<br/>Alpha-Synuclein Transcript Fate Control"]
B["Perturbation-First Validation Required<br/>METTL3/METTL14 Manipulation"]
C["m6A Epitranscriptomic Editing<br/>CasRx or small molecule inhibition"]
D["SNCA Aggregation Phenotype<br/>PD Model Systems Testing"]
E["Mechanism Validation<br/>Confirm m6A-SNCA-Aggregation Axis"]
F["PD Therapeutic Target<br/>m6A Writer Complex as Intervention Point"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#4a148c,stroke:#ce93d8,color:#ce93d8
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9aNo linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for N6- yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for N6-.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.